Intestinal autotransplantation

Guosheng Wu*

Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi’an, Shaanxi, China

*Corresponding author. Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, #127 Changle West Rd, Xi’an, Shaanxi 710032, China. Tel: +86-29–84771508; Fax: +86-29–82539041; Email: Guosheng_w@yahoo.com

Abstract

Most abdominal neoplasms involving the root of the superior mesenteric artery and/or celiac artery are difficult to manage with conventional operative techniques because of limited intestinal ischemia times and poor accessibility to the tumor region. Ex vivo surgery followed by intestinal autotransplantation (IATx) is a relatively novel surgical strategy to offer chances for complete resection in such hopeless circumstances. This review aims to assess potential surgical indications, operative techniques and clinical outcomes after IATx. Currently the main indications reported for IATx broadly include pancreatic, mesenteric and retroperitoneal neoplasms closely involving the superior mesenteric vessels. The preliminary results show that radical resection can be effectively achieved in carefully selective patients. Although perioperative morbidity and mortality are relatively high, there are several long-term survivors, particularly after complete resection of benign and low-grade tumor. Early tumor recurrence, however, remains a major problem in patients with high-grade tumor, particularly pancreatic ductal carcinoma. In conclusion, IATx allows patients with selected abdominal neoplasms involving the major mesenteric vessels to be completely resected. However, this aggressive approach is associated with a considerable operative risk, and should only be performed at experienced centers. Additional and adjunctive treatment therapies are required to improve the efficacy of this treatment.

Key words: Intestinal autotransplantation; ex vivo surgery; pancreatic cancer; mesenteric tumors

Introduction

Abdominal neoplasms involving the root of the superior mesenteric artery (SMA) and/or celiac artery are rare and consist of a heterogeneous group of benign and malignant lesions. These neoplasms may originate from any of mesenteric components, retroperitoneal tissues or the head of pancreas [1–3]. To date, complete surgical resection to obtain tumor clearance (R0 resection) is the primary goal and is essential to achieve better clinical outcomes [4]. However, an extensive surgical resection, particularly in the management of major mesenteric arterial and venous involvement, is a technically challenging procedure and is associated with high perioperative morbidity and mortality rates [5–7].

With advances in organ preservation and surgical strategies, ex vivo surgery and autotransplantation have been successful in the kidney, liver and heart [8–12]. Such techniques have broadened treatable diseases, ranging from complex vascular reconstructions to complicated surgical oncological cases. As an extension of the above ideas, an en bloc removal of a tumor together with the intestine, ex vivo resection and intestinal autotransplantation (IATx) was briefly described in 1996 by Li et al. [13] and was further described in detail in 2000 by Tzakis et al. [14]. The key feature for consideration of IATx involves techniques of organ preservation as used in intestinal allotransplantation. Potential benefits of ex vivo surgery included providing adequate surgical exposure, a bloodless operative field and hypothermic protection of the bowel against ischemic damage. To further refine this complex procedure, our team developed a modified method in which a
segmental bowel autograft is selected and is harvested first during the initial stage of the procedure and radical resection of the neoplasm is performed thereafter [15]. Our modification theoretically better protects a healthy bowel autograft from potential damage due to prolonged warm ischemia and allows the subsequent lengthy process of dissection to be performed in an unrushed manner.

The use of IATx has currently emerged as a potential surgical option for patients with selected abdominal neoplasms involving the root of the SMA. Because IATx is a highly specialized and technically complex procedure, only a few cases have been reported in the literature to date. In this review, we summarize surgical indications, technical considerations, potential complications and clinical outcomes after this procedure.

**Surgical indications**

A MEDLINE-assisted search was conducted in English publishing from January 1996 to October 2016 to identify patients in whom IATx was undertaken. Table 1 presents an overview of various indications for a total of 44 patients who underwent IATx. The pancreatic head neoplasms form the largest group (n = 28), followed by mesenteric-originated lesions (n = 12), retroperitoneal neoplasms (n = 2) and other diagnoses (n = 2).

**Pancreatic neoplasms**

Due to anatomic proximity, the head of pancreatic neoplasms frequently invades into the major mesenteric vasculature and

---

### Table 1. Details of patient characteristics and clinical outcomes (n = 44)

| Case | First author | Year | Sex/age (years) | Primary locations | Diagnosis | Survival (months)/status | Recurrence |
|------|--------------|------|----------------|-------------------|-----------|-------------------------|------------|
| 1    | Lai [36]     | 1996 | Male/56        | Pancreas          | Islet cell carcinoma | 18/alive   | None                    |
| 2    | Li [13]      | 1996 | Male/34        | Pancreas          | Adenocarcinoma      | 2/NA       | NA                      |
| 3    | Quintini [24]| 2007 | Male/43        | Pancreas          | Adenocarcinoma      | 15/dead    | Yes                     |
| 4    |              |      | Male/51        | Pancreas          | Adenocarcinoma      | 19/dead    | Yes                     |
| 5    | Zeng [25]    | 2008 | Male/21        | Mesentery         | Hemangiomia         | 9/alive    | None                    |
| 6    | Amano [23]   | 2009 | Female/57      | Pancreas          | Adenocarcinoma      | 11/dead    | Yes                     |
| 7    |              |      | Male/64        | Pancreas          | Adenocarcinoma      | 12/dead    | Yes                     |
| 8    | Kitchens [26]| 2011| Male/60        | Mesentery         | Carcinoid tumor     | 30/alive   | None                    |
| 9    | Kato [27]    | 2012 | Female/63      | Mesentery         | Leiomyosarcoma      | 38/alive   | None                    |
| 10   |              |      | Female/7       | Pancreas          | Inflammatory myofibroblastic tumor | 27/alive | None                    |
| 11   |              |      | Female/8       | Pancreas          | Kaposiform hemagioendothelioma | 17/alive | None                    |
| 12   | Tzakis [21]  | 2012 | Male/4         | Mesentery         | Fibroma             | 138/alive  | None                    |
| 13   |              |      | Male/5         | Mesentery         | Vascular dysplasia  | 117/alive  | None                    |
| 14   |              |      | Female/41      | Mesentery         | Desmoid tumor       | 67/dead    | None                    |
| 15   |              |      | Female/63      | Mesentery         | Leiomyosarcoma      | 26/alive   | None                    |
| 16   |              |      | Male/52        | Pancreas          | Adenocarcinoma      | 6/dead     | Yes                     |
| 17   |              |      | Male/0.5       | Pancreas          | Poorly differentiated tumor | 23/alive | None                    |
| 18   |              |      | Female/17      | Pancreas          | Solid cystic pseudopapillary tumor | 78/alive | None                    |
| 19   |              |      | Female/35      | Pancreas          | Solid pseudopapillary tumor | 13/alive | None                    |
| 20   |              |      | Female/38      | Pancreas          | Desmoid tumor       | 94/alive   | None                    |
| 21   | Tzvetanov [28]| 2012 | Male/38        | Jejunum           | Adenocarcinoma      | 8/dead     | Yes                     |
| 22   |              |      | Male/60        | Mesentery         | Desmoid tumor       | 36/alive   | Yes                     |
| 23   |              |      | Male/56        | Mesentery         | Desmoid tumor       | 30/alive   | None                    |
| 24   | Nikeghbalian [22]| 2014 | Female/52      | Pancreas          | Adenocarcinoma      | NA/alive   | None                    |
| 25   |              |      | Female/32      | Pancreas          | Adenocarcinoma      | NA/alive   | None                    |
| 26   |              |      | Male/45        | Pancreas          | Adenocarcinoma      | NA/alive   | None                    |
| 27   |              |      | Female/56      | Pancreas          | Adenocarcinoma      | NA/alive   | None                    |
| 28   |              |      | Male/46        | Pancreas          | Adenocarcinoma      | NA/alive   | None                    |
| 29   |              |      | Male/50        | Pancreas          | Adenocarcinoma      | 20/alive   | Yes                     |
| 30   |              |      | Male/73        | Pancreas          | Adenocarcinoma      | 6/dead     | Yes                     |
| 31   |              |      | Female/33      | Pancreas          | Adenocarcinoma      | NA/alive   | Yes                     |
| 32   |              |      | Female/58      | Pancreas          | Pseudotumor         | NA/alive   | None                    |
| 33   |              |      | Male/47        | Pancreas          | Pseudotumor         | NA/alive   | None                    |
| 34   |              |      | Female/16      | Retroperitoneum   | Rhabdomyosarcoma    | NA/alive   | None                    |
| 35   |              |      | Female/55      | Intestine         | Gastrointestinal stromal tumor | NA/alive | None                    |
| 36   | Wu [15, 51]  | 2016 | Male/63        | Mesentery         | Desmoid tumor       | 62/alive   | None                    |
| 37   |              |      | Male/53        | Mesentery         | Desmoid tumor       | 28/3/alive | None                    |
| 38   |              |      | Male/24        | Retroperitoneum   | Ganglioneuroma       | 21/dead    | None                    |
| 39   |              |      | Female/56      | Pancreas          | Solid pseudopapillary tumor | 43.9/alive | None                    |
| 40   |              |      | Female/67      | Pancreas          | Serous cystadenocarcinoma | 28.4/alive | None                    |
| 41   |              |      | Male/58        | Pancreas          | Neuroendocrine tumor | 13/9/alive | None                    |
| 42   |              |      | Female/20      | Pancreas          | Adenocarcinoma      | 12.4/alive | Yes                     |
| 43   |              |      | Male/32        | Pancreas          | Adenocarcinoma      | 10.9/alive | None                    |
| 44   |              |      | Male/52        | Pancreas          | Adenocarcinoma      | 5.9/alive  | None                    |

NA, not available.
retroperitoneal tissue (Figure 1A, B, C and D). A complete resection is essential to obtain long-term survival and has become an acceptable option for neoplasms involving the root of the SMA and/or celiac artery [16,17]. However, an extensive pancreaticoduodenectomy, particularly in the management of major arterial and venous involvement, has remained an issue of controversial debate due to high perioperative morbidity and mortality rates and inconsistent oncological outcomes [5,18,19]. An attempted resection by conventional surgery may result in uncontrolled bleeding, irreversible intestinal ischemic damage or a non-curative resection (R1 or R2) [20]. An extensive pancreaticoduodenectomy together with IATx has been used by various authors to improve curative-intent resection rates [21–24]. In the 28 pancreatic head neoplasms undergoing IATx, most are pancreatic ductal carcinoma (n = 18), while solid cystic pseudopapillary tumor (n = 3) and other rare diagnoses (n = 7) are also present (Table 1).

Mesenteric neoplasms
Primary mesenteric tumors are rare but can often be complex and difficult to manage. In the literature, potential indications for IATx have included desmoid tumor (n = 5), leiomyosarcoma (n = 2), complex vascular abnormalities (n = 2) and other diagnoses (n = 2) [14,15,21,25–28]. Mesenteric desmoid tumors involving the major mesenteric vasculature are most indicated for IATx. These tumors are progressive fibroblastic and fibrotic proliferations arising from the mesentery. They may occur sporadically, or in the context of familial adenomatous polyposis (FAP) or Gardner’s syndrome [29,30]. The frequency of desmoid tumors in patients with familial polyposis ranges from 4% to 32% in various reports, but only 8% of desmoid tumors are localized to the mesentery [31,32]. They have a tendency to aggressively invade major vascular structures, often obstruct the bowel and recur repeatedly. Despite their benign histologic appearance and negligible metastatic potential, their infiltrative features of growth can ultimately lead to life-threatening patterns of visceral involvement (Figure 1E). These characteristic makes the treatment of these relatively rare fibrous tumors challenging. Surgical treatment is the only therapy of demonstrated benefit for desmoid tumors. Local recurrent rates after conservative resection range from 39% to 70%. Aggressive, wide local resection remains the treatment of choice for most of patients with desmoid tumors and complete surgical excision of desmoid tumors.
with a negative surgical margin is the most effective method of cure. However, complete resection is not always feasible because of difficulty in differentiating the desmoid tumor from adjacent tissue, and involvement of major mesenteric vessels.

**Retropertitoneal neoplasms**

Primary retropertitoneal neoplasms are relatively rare lesions with a diverse group of benign and malignant tumors originating from the retropertitoneal space [33,34]. Retropertitoneal neoplasms usually grow slowly with no symptoms at the early stage and tend to be extremely large at presentation. At the time of diagnosis, tumors may have surrounded and invaded vital organs and major vascular structures, making complete surgical resection difficult to achieve (Figure 1F). Local recurrence after incomplete surgical resection is frequently related to the large tumor size, the inability to achieve wide surgical margins, and the limitations of adjuvant radiation and chemotherapy [35]. Therefore, an optimal surgical approach that allows a complete resection of retropertitoneal neoplasms, whilst protecting important blood vessels, tissues and organs, is required to improve poor outcomes. The surgical indications for IATx included rhabdomyosarcoma (n = 1) and ganglioneuroma (n = 1).

IATx has also been used to treat malignant neoplasms originating from the proximal jejunum encasing the root of the SMA (n = 2). In addition, we recently used the IATx approach to treat a case with a huge isolated pseudoaneurysm of the SMA that was not manageable by endovascular stenting or conventional open surgery, but was successfully managed by IATx.

**Pre-operative work-up**

Thorough pre-operative evaluation is essential before proceeding to IATx. Prior to the procedure, our multidisciplinary team assesses thoroughly each case, particularly for the extent of the disease, the metastatic potential of the neoplasm and the estimated chance of survival without resection. Particular attention is paid to imaging studies, oncologic review of prior therapy, evaluation of cardiopulmonary risk, and nutritional and psychosocial assessments.

Imaging studies must specifically address several pertinent points when evaluating potential patients for IATx, including involvement of the major vasculature (the superior mesenteric vessels, the celiac axis and the hepatic artery), regional lymphadenopathy and local invasion of other structures. Non-invasive CT angiography with 3D reconstruction or conventional selective angiography was used to evaluate the superior mesenteric vessels prior to surgery.

**Special technical considerations**

Surgical procedures primarily consist of three distinct operations: selection and preparation of appropriate bowel autograft, extensive pancreaticoduodenectomy and IATx. Detailed descriptions of these operative procedures are well described in the literature and are beyond the scope of this review. The technical considerations of each procedure are outlined.

**Exploration and decision for IATx**

Surgical exposure for a pancreaticoduodenectomy is first obtained either through an upper midline incision or a bilateral subcostal incision. The abdominal cavity is carefully assessed for evidence of distant metastatic diseases beyond a primary tumor, particularly the liver, peritoneal surfaces, duodenojejunal flexure and pelvic cavity. The lesser sac is opened with the assessment of the hepatic and celiac arteries for tumor involvement. The pancreatic head and duodenum are mobilized to assess involvement of the superior mesenteric vein (SMV) and SMA with tumor. Lesions that are suspicious for cancer are biopsied and sent for frozen section analysis. Upon confirming the extent of the tumor involvement and excluding distal metastasis, a final decision is usually made to proceed with IATx.

**In situ or ex vivo surgery**

Basically, there are two different approaches to accomplish IATx. In situ IATx was the early method described by Lai et al. [36]. He presented a case with a locally advanced nonfunctioning islet cell carcinoma that underwent radical total pancreatectomy, gastrectomy, colectomy, hepatic revascularization and in situ IATx without hypothermic perfusion. Amano et al. also used this approach for two patients with pancreatic ductal carcinoma [23]. In the literature, most authors used an ex vivo approach to accomplish tumor resection followed by IATx, similarly to the method developed by intestinal allotransplantation. In this technique, a tumor together with the root of the mesentery, the partial or whole pancreas, duodenum, intestine and right colon were removed en bloc and were in vitro flushed through the SMA with chilled preservation solution [14,24,37,38]. Upon the tumor being completely resected at the back-table, the intestinal autograft was implanted with vascular and gastrointestinal reconstruction. These maneuvers allow tumor resection and vascular reconstruction in a bloodless surgical field with minimal injury to the explanted organs. We further developed a modified method as we used in living donor intestinal allotransplantation [15]. In this modification, a segmental bowel autograft is initially selected and harvested during an earlier stage of the operation, and complete resection of the neoplasm is carried out next. We believe this change would better protect a healthy bowel autograft from potential damage due to prolonged warm ischemia and allow the subsequent lengthy process of dissection to be performed in an unrushed manner. Furthermore, the alteration would better adhere to the general principles of minimal tumor manipulation during operation and potentially decrease the risks of tumor implantation during in vitro organ perfusion. Our initial experience indicates that this technique is safe and effective to assist RO resection.

A suitable segment of the intestine with a reasonably sized SMA for vascular anastomosis is initially selected below the tumor and is measured for future grafting. The location of a distal branch of the SMA supplying the future segmental graft can be identified with palpation and transillumination; the SMV can usually be found on the right anteriolateral aspect of the SMA. The mesentery is then divided in a ‘V’ shaped fashion with the tip of the ‘V’ at the takeoff of the vessel. The bowel graft is marked with a simple stitch to recognize proximal and distal ends, and divided using a gastrointestinal anastomosis stapler. Once the vessels are transected at the designed line, the graft is removed and flushed immediately through the artery with cold histidine-tryptophan-ketoglutarate (HTK) solution until clear return from the vein is obtained. Then, the bowel graft is kept chilled in preservation solution until use (Figure 2).

**Back-table preparation and use of vascular graft**

Either the University of Wisconsin Solution (UW) or HTK has successfully been used as a preservation solution. In our
experience, we prefer to use HTK in terms of the low potassium content that reduces the risk of cardio-circulatory complications after reperfusion, and the low viscosity that allows fast and homogenous intestine perfusion.

In most cases, the intestinal autograft SMA and SMV can be directly used with no vascular autograft for reconstruction. In the case of shorter vascular vessels of an intestinal graft, interpositional graft is used to facilitate vascular reconstruction (Figure 2B). In addition to meticulous surgical skills, selection of appropriate vascular grafts is very important to accomplish the procedure and avoid post-operative complications. In the literature, three different vascular grafts including an autograft, allo- and artificial graft have been used. Nikeghbalian et al. reported two cases with decreased donor vascular grafts under immunosuppressive and both patients died due to severe surgical complications, including uncontrolled sepsis and thrombosis-caused small bowel necrosis [22]. Other authors did not report vascular allograft-related complications. Kato et al. reported three cases of multivisceral ex vivo surgery followed by vascular reconstruction by synthetic vascular grafts without complications [27]. A vascular autograft from the internal jugular vein, saphenous vein or internal iliac artery was also used with good outcomes. In our practice, we prefer to use a vascular autograft in case of needs instead of a synthetic graft or decreased donor vascular allograft. Special attention should be paid to avoid the endothelial damage or detachment from the muscular layer.

Gastrointestinal reconstruction

In most cases, pancreaticojunostomy is commonly performed with a duct-to-mucosa technique. We prefer to place a pancreatic duct stent to reduce a pancreatic leak. Anastomosis of the pancreatic remnant to the posterior wall of the stomach is also used to decrease the risk of pancreatic fistula. The hepaticojejunostomy is performed downstream from the pancreatic anastomosis in an end-to-side manner. Continuity of the gastrointestinal tract is reconstructed using a 45- to 50-cm Roux-en-Y limb to complete pancreaticoenterostomy, choledochoenterostomy, gastroenterostomy and ileocolostomy.

Surgical complications and management

Table 2 summarizes the surgical procedures and perioperative outcomes for the 44 patients who underwent IATx.

Perioperative mortality

With increase in experience and specialization, pancreaticoduodenectomy in some high-volume centers can be performed with a perioperative mortality of 1–3% [40,41]. Theoretically, the extensive pancreaticoduodenectomy together with IATx may be associated with a high level of mortality. With a total of 44 patients undergoing IATx over a 20-year period, 4 (9.1%) died during the initial hospital stay and the causes of death were multi-organ failure, infection, pancreatic leak and cerebrovascular accident, respectively [15,22].

Portal versus systemic drainage

Either the portal venous or systemic drainage can be applied to accomplish vascular reconstruction. Theoretically, portal venous drainage is more physiological than systemic drainage due to the hepatotropic effects of the portal blood. In our center, the portacaval anastomosis is frequently used as an anastomotic location because of its shorter graft vein. Similarly to intestinal allotransplantation, the systemic venous drainage usually carries a low risk of dramatic metabolic consequences in the presence of normal liver function [39].

Early graft loss

The intestine autograft loss caused by SMA thrombosis is a serious early complication after IATx. Early SMA thrombosis occurred in 3 of the 44 cases and portal vein thrombosis occurred in 1 case after surgery [15,21,22,26]. All four cases were complicated with bowel necrosis, and entire autograft loss in three and partial loss in one. Early detection of this complication is critical to avoid irreversible bowel damage, although a strategy to make a definitive diagnosis is currently lacking [42,43]. Serum lactic acid may be a useful marker for detecting intestinal ischemic

Figure 2. An intra-operative photograph demonstrating how intestinal autotransplantation is undertaken. (A) Bowel autograft is flushed through graft artery with cold preservation solution. (B) Internal iliac artery autograft is procured and used for extension. (C) Bowel autograft is kept chilled in preservation solution until use. (D) Bowel autograft returned to a pink color immediately after reperfusion.
Post-operative pancreatic leakage is one of the most serious complications after pancreaticoduodenectomy [44]. The rate of pancreatic anastomotic leak ranges from 8% to 18% of patients undergoing routine pancreaticoduodenectomy at major centers, which contributes significantly to the morbidity and mortality [40,45]. Patients who undergo an extensive pancreaticoduodenectomy together with IATx may be at particular risk of developing leakage from the pancreatic anastomosis. In the literature, confirmed leakage from the pancreaticoenterostomy occurred in 2 of the 44 patients with IATx (4.8%). One case with a small leak was successfully managed without surgery. We reported a case with an anastomotic leak at the pancreaticojejunostomy and the patient died 3 weeks after the procedure [15]. This case presented with high fever, abdominal distention, ileus and leukocytosis with mildly increased amylase and lipase in the peritoneal drainage. CT showed a localized fluid collection in the region of the pancreaticojejunalostomy without an air-fluid level. Exploratory laparotomy confirmed a fistula from the pancreaticojejunal anastomosis, possibly related to ischemic necrosis of the remaining pancreatic tail. After a thorough wash and debridement of nonviable pancreatic tissue, the patient developed a massive intraperitoneal hemorrhage from the disrupted SMA anastomosis and died of severe hypovolemic shock. Therefore, great concern should always be given to appropriate management of the pancreatic remnant during IATx. The adequacy of blood supply at the cut surface of the pancreas should be evaluated routinely and, if deemed inadequate, more of the pancreas should be removed or even a total pancreatectomy may be considered to avoid this deadly complication.

A combination of optimization of blood supply to the pancreatic remnant, a meticulous operative technique and appropriate selection of pancreaticoenterostomy or pancreaticojejunostomy should be considered to reduce this deadly complication.

### Delayed gastric emptying

Delayed gastric emptying in the absence of any mechanical obstruction is one of the most common post-operative complications after pancreatic surgery [46,47]. This complication may be related to denervation of the upper gastrointestinal tract during dissection of the pancreatic head and the superior mesenteric vessels [48]. Delayed gastric emptying usually resolves in 4–12 weeks in most patients after pancreatic surgery. It is unclear regarding the rate and severity of this complication after extensive pancreaticoduodenectomy and IATx. In our series, 2 of 10 patients had delayed gastric emptying that was successfully managed with conservative treatment. We usually place a gastrostomy tube at the time of surgery to relieve symptoms and insert a feeding jejunostomy tube to deliver enteral feeding.

### Post-operative hemorrhage

Early intra-abdominal bleeding within 24 hours of surgery may require reoperation for hemostasis. In the literature, one case had an intra-abdominal hematoma within 48 hours post-operatively which required reoperations [24]. Delayed bleeding more than 1 week after surgery may be related to pancreatic fistula with erosion into retroperitoneal vessels [15]. In our opinion, this potentially lethal complication is best managed with early exploratory laparotomy to exclude pancreatic fistula.

### Clinical outcomes

Tumor recurrence appears to be a major problem in patients with high-grade advanced cancer after IATx. In 18 patients with pancreatic ductal adenocarcinoma, 7 out of 11 patients with a documented follow-up time had tumor recurrence at short-term median follow-up of 11.5 months (range, 5.9–20 months). Among them, five patients died at the time of follow-up and...
two were under chemotherapy. Clearly, adjunctive therapies including chemotherapy and/or radiation may be required to improve tumor clearance after IATx.

The best outcomes can be achieved in patients with a diagnosis of benign or low-grade malignant lesions. In six patients with desmoid tumor, only one had tumor occurrence at a median follow-up of 36 months and the other five patients remained recurrence-free at a median follow-up of 52.9 months (range, 28.3–94 months). It appears that curative surgery is the best treatment option for this group of patients.

Long-term nutritional outcomes have not been well described in the literature. Based on our experience and others with living-related intestinal allotransplantation, a 160- to 180-cm length of an ileal graft is sufficient to support an adult [49,50]. Considering a 45- to 50-cm Roux-en-Y limb, we suggest that a minimum length of 200 cm for a bowel autograft is required for completing the gastrointestinal reconstruction and achieving nutritional autonomy [15]. In 33 patients with a documented length of bowel graft, the length of the transplanted intestinal autografts more than 130 cm, only one patient who received 40 cm of bowel required total parenteral nutrition (TPN) and later died of urosepsis. Most successful bowel autografts did not require TPN or any supplemental parenteral nutrition or intravenous fluids after hospital discharge. Early mild, controllable diarrhea was suggestive of rapid intestinal transit time with the lack of a right colon but did not affect the adequacy of nutritional absorption.

**Summary**

IATx has been used to treat the pancreatic, mesenteric and retroperitoneal neoplasms encasing the root of the SMA and/or celiac artery. This complex approach may prove to be an effective option for highly selected patients with reasonable clinical outcomes. The procedure allows patients with locally advanced abdominal neoplasms involving the major mesenteric vessels to be resected completely and result in early intestinal autonomy from parenteral nutrition. Careful pre-operative assessment and planning will maximize the chance for a safe and uncomplicated pancreaticoduodenectomy and potentially minimize local tumor recurrence. This operative strategy is technically demanding and probably should be performed only at centers experienced with intestinal transplantation.

**Acknowledgements**

The authors would like to thank the surgical team and the nursing staff at the Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, for their excellent patient care. The authors thank Mr Yingjun Wu for help with English grammar. This work is supported by the grant from the National Natural Science Foundation of China (#81570588). Ethics committee approval was obtained from Xijing Hospital, The Fourth Military Medical University.

**Conflict of interest statement:** none declared.

**References**

1. Dufay C, Abdelli A, Le Pennc V et al. Mesenteric tumors: diagnosis and treatment. J Visc Surg 2012;149:4239–51.
2. Gemici K, Buldu I, Acan T et al. Management of patients with retroperitoneal tumors and a review of the literature. World J Surg Oncol 2015;13:143.
3. Tseng JF, Raut CP, Lee JE et al. Pancreatectoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935–50.
4. Liu L, Katz MH, Lee SM et al. Superior mesenteric artery margin of posttherapy pancreaticoduodenectomy and prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 2015;39:1395–1403.
5. Mollberg N, Rahbari NN, Koch M et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 2011;254:882–93.
6. Martin RC, Jr, Scoggin CR, Egnatashvili V et al. Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes. Arch Surg 2009;144:154–9.
7. Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg 2010;14:1442–52.
8. Wotkowicz C, Libertino JA. Renal autotransplantation. BJU Int 2004;93:253–7.
9. Azhar B, Patel S, Chadha P et al. Indications for renal autotransplant: an overview. Exp Clin Transplant 2015;13:109–14.
10. Fichlmayr R, Grosse H, Hauss J et al. Technique and preliminary results of extracorporeal liver surgery (brench procedure) and of surgery on the in situ perfused liver. Br J Surg 1999;77:21–6.
11. Conklin LD, Reardon MJ. Autotransplantation of the heart for primary cardiac malignancy: development and surgical technique. Tex Heart Inst J 2002;29:105–8.
12. Raab R, Schlitt HJ, Oldhafer KJ et al. Ex-vivo resection techniques in tissue-preserving surgery for liver malignancies. Langenbecks Arch Surg 2000;385:179–84.
13. Li CL, Lyu XZ, Zhao GX et al. Extensive pancreaticoduodenectomy combined with small bowel autotransplantation for pancreatic cancer: a case report. Zhonghua Wai Ke Za Zhi 1996;34:757.
14. Tzakis AG, De Faria W, Angelis M et al. Partial abdominal exten-teration, ex vivo resection of a large mesenteric fibroma, and successful orthotopic intestinal autotransplantation. Surgery 2000;128:486–9.
15. Wu G, Zhao Q, Wang W et al. Clinical and nutritional outcomes after intestinal autotransplantation. Surgery 2016;159:1668–76.
16. Hackert T, Schneider L, Buchler MW. Current state of vascular resections in pancreatic cancer surgery. Gastroenterol Res Pract 2015;2015:120207.
17. Werner J, Combs SE, Springfield C et al. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol 2013;10:323–33.
18. Gluth A, Werner J, Hartwig W. Surgical resection strategies for locally advanced pancreatic cancer. Langenbecks Arch Surg 2015;400:757–65.
19. Michalski CW, Kleeff J, Wente MN et al. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 2007;94:265–73.
20. Christians KK, Pilgrim CH, Tsai S et al. Arterial resection at the time of pancreatectomy for cancer. Surgery 2014;155:919–26.
21. Tzakis AG, Pararas NB, Tekin A et al. Intestinal and multivisceral autotransplantation for tumors of the root of the mesentery: long-term follow-up. Surgery 2012;152:82–9.
22. Nikhefbahian S, Aliakbarian M, Kazemi K et al. Ex-vivo resection and small-bowel auto-transplantation for the treatment of tumors at the root of the mesentery. Int J Organ Transplant Med 2014;5:120–4.
23. Amano H, Miura F, Toyota N et al. In situ surgical procedures for locally advanced pancreatic cancer: partial abdominal evisceration and intestinal autotransplantation. J Hepatobiliary Pancreat Surg 2009;16:771–6.

24. Quintini C, Di Benedetto F, Diago T et al. Intestinal autotransplantation for adenocarcinoma of pancreas involving the mesenteric root: our experience and literature review. Pancreas 2007;34:266–8.

25. Zeng Y, Wu H, Yang JY. Small bowel autotransplantation combined with pancreateo-duodenectomy for enormous cavernous hemangioma of the small intestine mesentery. Chin Med (Engl) 2008;121:2110–12.

26. Kitchens WH, Elias N, Blaszkowsky LS et al. Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor. World J Surg Oncol 2011;9:11.

27. Kato T, Lobritto SJ, Tzakis A et al. Multivisceral ex vivo surgery for tumors involving celiac and superior mesenteric arteries. Am J Transplant 2012;12:1323–8.

28. Tzvetanov IG, Bhati CS, Jeon H et al. Intra-abdominal desmoid tumors of the mesentery root: initial experience. Surgery 2012;151:621–4.

29. Koskenvuo L, Peltomaki P, Renkonen-Sinisalo L et al. Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis. J Surg Oncol 2016;113:209–12.

30. Ogawa N, Iseki H, Tsunozaki H et al. Intra-abdominal desmoid tumor difficult to distinguish from a gastrointestinal stromal tumor: report of two cases. Surg Today 2014;44:2174–9.

31. Mullen JT, Delaney TF, Kobayashi WK et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 2012;19:4028–35.

32. Mezhir JJ. The desmoid tumor: still an enigma. J Surg Res 2012;173:46–8.

33. Neville A, Herts BR. CT characteristics of primary retroperitoneal neoplasms. Crit Rev Comput Tomogr 2004;45:247–70.

34. Osman S, Lehnert BE, Elojeimy S et al. A comprehensive review of the retroperitoneal anatomy, neoplasms, and pattern of disease spread. Curr Probl Diagn Radiol 2013;42:191–208.

35. Strauss DC, Hayes AJ, Thomas JM. Retroperitoneal tumours: review of management. Ann R Coll Surg Engl 2011;93:275–80.

36. Lai DT, Chu KM, Thompson JF et al. Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation. Surgery 1996;119:112–14.

37. Tzakis AG, Kato T, Mittal N et al. Intestinal autotransplantation for the treatment of pathologic lesions at the root of the mesentery. Transplant Proc 2002;34:908–9.

38. Tzakis AG, Tryphonopoulos P, De Faria W et al. Partial abdominal evisceration, ex vivo resection, and intestinal autotransplantation for the treatment of pathologic lesions of the root of the mesentery. J Am Coll Surg 2003;197:770–6.

39. Berney T, Kato T, Nishida S et al. Portal versus systemic drainage of small bowel allografts: comparative assessment of survival, function, rejection, and bacterial translocation. J Am Coll Surg 2002;195:804–13.

40. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10–15.

41. Keck T, Wellner UF, Bahra M et al. Pancreatogastrostomy versus pancreateojunostomy for REConstruction After PANCreatoduodenectomy (RECOFANC, DRKS 0000767): perioperative and long-term results of a multicenter randomized controlled trial. Ann Surg 2016;263:440–9.

42. Matsumoto S, Sekine K, Funaoka H et al. Diagnostic performance of plasma biomarkers in patients with acute intestinal ischemia. Br J Surg 2014;101:232–8.

43. van den Heijkant TC, Aerts BA, Teijink JA et al. Challenges in diagnosing mesenteric ischemia. World J Gastroenterol 2013;19:1338–41.

44. Ramacciato G, Mercantini P, Petruccioni N et al. Risk factors of pancreatic fistula after pancreaticoduodenectomy: a collective review. Am Surg 2013;77:257–69.

45. Menahem B, Guittet L, Mulliri A et al. Pancreatogastrostomy is superior to pancreateojunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Ann Surg 2015;261:882–7.

46. Hanna MM, Gadde R, Tamariz L et al. Delayed gastric emptying after pancreaticoduodenectomy: is subtotal stomach preserving better or pylorus preserving? J Gastrointest Surg 2015;19:1542–52.

47. El Nakeeb A, Askr W, Mahdy Y et al. Delayed gastric emptying after pancreaticoduodenectomy: risk factors, predictors of severity and outcome: a single center experience of 588 cases. J Gastrointest Surg 2015;19:1093–1100.

48. Hanna MM, Gadde R, Allen CJ et al. Delayed gastric emptying after pancreaticoduodenectomy. J Surg Res 2016;202:380–8.

49. Fan DM, Zhao QC, Wang WZ et al. Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. Am J Transplant 2015;15:1432–5.

50. Benedetti E, Holterman M, Asolati M et al. Living related segmental bowel transplantation: from experimental to standardized procedure. Ann Surg 2006;244:694–9.

51. Wu G, Wang X, Zhao Q et al. Intestinal autotransplantation for neoplasms originating in the pancreatic head with involvement of the superior mesenteric artery. Langenbecks Arch Surg 2016;401:1249–57.